2189684-44-2|HIV抑制剂GS-6207|Lenacapavir|No data available-范德生物科技公司

HIV抑制剂GS-6207

NMR下载 COA and HPLC MSDS下载
names：
Lenacapavir
CAS号：
2189684-44-2
MDL Number： No data available
MF(分子式)： C39H32ClF10N7O5S2 MW(分子量)： 968.28
EINECS:No data available Reaxys Number:No data available
Pubchem ID:133082658 Brand:BIOFOUNT

HIV 抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)是一种 HIV-1 衣壳抑制剂。在 MT-4 细胞中，Lenacapavir 具有抗 HIV 活性，EC₅₀ 为 100 pM，在外周血单个核细胞中，对 23 种来自不同亚型的 HIV-1 临床分离株的平均 EC₅₀ 为 50 pM (20-160 pM)。

货品编码	规格	纯度	价格 (¥)	现价(¥)	库存描述	数量	总计 (¥)
YZM000675-10mg	10mg	>97%	¥ 2230.00	¥ 2230.00	1-3天	- +	¥ 0.00
YZM000675-5mg	5mg	>97%	¥ 1420.00	¥ 1420.00	1-3天	- +	¥ 0.00
YZM000675-1mg	1mg	>97%	¥ 500.00	¥ 500.00	1-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	HIV-1衣壳抑制剂GS-6207(2189684-44-2);GS-6207;
英文别名	GS-6207(2189684-44-2);GS-CA1;Lenacapavir;
CAS号	2189684-44-2
SMILES	FC1=CC(F)=CC(C[C@@H](C2=NC(C#CC(S(=O)(C)=O)(C)C)=CC=C2C3=CC=C(Cl)C4=C3N(CC(F)(F)F)N=C4NS(=O)(C)=O)NC(CN5C(C(F)(F)[C@@]6([H])[C@]7([H])C6)=C7C(C(F)(F)F)=N5)=O)=C1
Inchi	InChI = 1S / C39H32ClF10N7O5S2 / c1-36（2,63（3,59）60）10-9-21-5-6-22（23-7-8-26（40）30-32（23）57（ 17-37（43,44）45）54-35（30）55-64（4,61）62）31（51-21）27（13-18-11-19（41）14-20（42） 12-18）52-28（58）16-56-34-29（33（53-56）39（48,49）50）24-15-25（24）38（34,46）47 / h5- 8,11-12,14,24-25,27H，13,15-17H2,1-4H3，（H，52,58）（H，54,55）/ t24-，25 +，27- / m0 / s1
InchiKey	BRYXUCLEHAUSDY-WEWMWRJBSA-N
分子式 Formula	C39H32ClF10N7O5S2
分子量 Molecular Weight	968.28
闪点 FP	No data available
熔点 Melting point	No data available
沸点 Boiling point	No data available
Polarizability极化度	No data available
密度 Density	1.6±0.1克/厘米3
蒸汽压 Vapor Pressure	No data available
溶解度Solubility
性状	Solid
储藏条件 Storage conditions	-20°C

HIV抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:GS-6207试剂,GS-6207杂质,GS-6207中间体,GS-6207密度,GS-6207溶解度,GS-6207旋光度,GS-6207闪点,GS-6207熔点,GS-6207结构式,GS-6207购买,

产品说明	HIV-1衣壳抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)是一种有效的HIV-1衣壳的抑制剂
Introduction	HIV-1衣壳抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)is aHIV capsidinhibitor. GS207 shows antiIV activity with anEC50of 100 pM in MT cells.
Application1	GS207 displays a meanEC50of 50 pM (2060 pM) against 23 HIV clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).
Application2
Application3

HIV-1衣壳抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)药理学：

Lenacapavir (GS-6207) 是一种 HIV-1 衣壳抑制剂。在 MT-4 细胞中，Lenacapavir 具有抗 HIV 活性，EC₅₀ 为 100 pM，在外周血单个核细胞中，对 23 种来自不同亚型的 HIV-1 临床分离株的平均 EC₅₀ 为 50 pM (20-160 pM)。

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV Phase 2 Recruiting 2020-08-27

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Re

Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in HIV-1 Infected Adults Phase 1 Completed 2020-07-08

Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227.

John O Link, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Jul 1.

HIV-1衣壳抑制剂GS-6207(2189684-44-2,Lenacapavir,GS-6207)参考文献：

1、Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE) Brief

Summary: The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with HIV (PLWH).

2、Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

Brief Summary: The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR).

3、Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in HIV-1 Infected Adults

Brief Summary: This study has 2 parts: Part A (Cohorts 1-5) and Part B (Cohorts 6-8). The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are experienced but capsid inhibitor (CAI) naive. Part B: To evaluate the short-term antiviral activity of tenofovir alafenamide (TAF) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day 10 in HIV-1 infected adult subjects who are antiretroviral treatment naïve or are experienced but without resistance to TAF.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开